U.S. Patent Office Issues Guidance to Examiners on Supreme Court's Myriad Decision

14 June 2013 Cleantech & Nano Publication

Today the USPTO issued guidance (PTO_Myriad_Guidelines) to Examiners on how to apply the Myriad Supreme Court decision to applications under examination. The guidance states that claims drawn “solely to naturally occurring nucleotide sequences or fragments” should be rejected for lack of eligibility under 35 U.S.C. 101. The guidance indicates that this is only a preliminary guidance memo, and that a more detailed guidance document will be issued to examiners in the future.

As noted in our earlier post, the Myriad decision has left plenty of room for nanotech patents, despite the finding that naturally occurring genes are unpatentable. The USPTO’s preliminary guidance appears in line with the decision and does not alter that general view.

Related Services


Hatch Comments on DNC-Related Construction Projects in Milwaukee
14 June 2019
Milwaukee Business Journal
Bernard Quoted on Debt-Relief Settlement with ITT Tech Lender
14 June 2019
Wall Street Journal
Dodd and Daughter Profiled in Wisconsin Golf
13 June 2019
Wisconsin Golf
Brinckerhoff Comments on SCOTUS Ruling in Patent Case
11 June 2019
Intellectual Property Magazine
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
2019 NDI Executive Exchange
14-15 November 2019
Chicago, IL
Association for Corporate Counsel Annual Meeting 2019
27-30 October 2019
Phoenix, AZ
Foley's Government Contracts Annual Update
16 October 2019
Liviona, MI